Ophelia, a NYC-based healthcare tech startup providing treatment for Opioid Use Disorder (OUD), raised $15m in Series A funding.
The round was led by Menlo Ventures with participation from Y Combinator, General Catalyst, Refactor Capital, and the founders of Flatiron Health, Warby Parker, Harry’s, Allbirds, PillPack, Carbon Health, and Lambda School.
The company intends to use the funds to continue to build and expand its services to patients across the U.S., to soon accept insurance, including Medicare and Medicaid.
Led by Zack Gray, Co-founder and CEO, Ophelia offers an alternative to traditional rehab for the treatment of OUD. Through its telemedicine platform, the company provides Medication-Assisted Treatment (MAT) in a private way for patients who otherwise have no way to access care. MAT works through a combination of medication to stop opioid withdrawal and cravings, plus support and therapy for patients when helpful.
The company also announced the addition of Dr. Darshak Sanghavi to its leadership team. Dr. Darshak Sanghavi, MD, who has been working with Ophelia in a leadership role to help the company grow and expand its relationships with insurance providers, has a diverse range of leadership experiences at the highest levels of academic medicine, government, and the nation’s largest commercial insurer and health services provider. Recently Chief Medical Officer at UnitedHealthcare and OptumLabs, Director of Prevention and Population Health at the Centers for Medicare and Medicaid Services during the Obama administration, and a leading researcher on substance use disorders, Dr. Sanghavi brings a wealth of experience in clinical strategy, clinical affordability, and medical policy to Ophelia.